Regeneron Pharmaceuticals, Inc. (REGN) stock
REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/3011% above fair value
$945.53−12.23 (-1.28%)
Close on Nov 18, 2026Market cap $97.81BP/E 20.9Yield –
Regeneron Pharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Regeneron Pharmaceuticals's free cash flow for the twelve months ending Sep 30, 2026 was $3.83B, down 9.4% year over year. For fiscal 2025 it was $4.08B, up 11.3% from the year before. Over ten years it grew 20.1% a year on average. The highest annual figure on record is $6.53B in fiscal 2021.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.08B | +11.3% |
| FY2024 | Dec 31, 2024 | $3.66B | -5.4% |
| FY2023 | Dec 31, 2023 | $3.88B | -12.4% |
| FY2022 | Dec 31, 2022 | $4.42B | -32.2% |
| FY2021 | Dec 31, 2021 | $6.53B | +225.9% |
| FY2020 | Dec 31, 2020 | $2.00B | +0.2% |
| FY2019 | Dec 31, 2019 | $2.00B | +10.4% |
| FY2018 | Dec 31, 2018 | $1.81B | +75.2% |
| FY2017 | Dec 31, 2017 | $1.03B | +6.2% |
| FY2016 | Dec 31, 2016 | $974.00M | +49.2% |
| FY2015 | Dec 31, 2015 | $652.85M | +55.7% |
| FY2014 | Dec 31, 2014 | $419.43M | -3.0% |
| FY2013 | Dec 31, 2013 | $432.27M | – |
| FY2012 | Dec 31, 2012 | -$123.95M | – |
| FY2011 | Dec 31, 2011 | -$198.90M | – |
| FY2010 | Dec 31, 2010 | -$467.00K | – |
| FY2009 | Dec 31, 2009 | -$167.25M | – |
| FY2008 | Dec 31, 2008 | -$123.94M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.48B | +4.6% |
| Q2 FY2026 | Jun 30, 2026 | $572.80M | -38.1% |
| Q1 FY2026 | Mar 31, 2026 | $848.30M | +4.0% |
| Q4 FY2025 | Dec 31, 2025 | $922.00M | -13.3% |
| Q3 FY2025 | Sep 30, 2025 | $1.42B | +35.1% |
| Q2 FY2025 | Jun 30, 2025 | $925.40M | +433.4% |
| Q1 FY2025 | Mar 31, 2025 | $815.80M | -40.8% |
| Q4 FY2024 | Dec 31, 2024 | $1.06B | +26.8% |
| Q3 FY2024 | Sep 30, 2024 | $1.05B | +11.8% |
| Q2 FY2024 | Jun 30, 2024 | $173.50M | -80.9% |
| Q1 FY2024 | Mar 31, 2024 | $1.38B | +15.9% |
| Q4 FY2023 | Dec 31, 2023 | $838.30M | -46.5% |
| Q3 FY2023 | Sep 30, 2023 | $938.30M | +92.9% |
| Q2 FY2023 | Jun 30, 2023 | $909.40M | +121.4% |
| Q1 FY2023 | Mar 31, 2023 | $1.19B | -39.3% |
| Q4 FY2022 | Dec 31, 2022 | $1.57B | -29.3% |
| Q3 FY2022 | Sep 30, 2022 | $486.40M | -85.2% |
| Q2 FY2022 | Jun 30, 2022 | $410.80M | -14.1% |
| Q1 FY2022 | Mar 31, 2022 | $1.96B | +254.3% |
| Q4 FY2021 | Dec 31, 2021 | $2.22B | +107.3% |
| Q3 FY2021 | Sep 30, 2021 | $3.28B | – |
| Q2 FY2021 | Jun 30, 2021 | $478.20M | -41.2% |
| Q1 FY2021 | Mar 31, 2021 | $553.20M | +4.8% |
| Q4 FY2020 | Dec 31, 2020 | $1.07B | +65.0% |
| Q3 FY2020 | Sep 30, 2020 | -$407.50M | -193.5% |
| Q2 FY2020 | Jun 30, 2020 | $813.50M | +768.2% |
| Q1 FY2020 | Mar 31, 2020 | $527.90M | -35.8% |
| Q4 FY2019 | Dec 31, 2019 | $648.40M | +0.8% |
| Q3 FY2019 | Sep 30, 2019 | $435.60M | +25.6% |
| Q2 FY2019 | Jun 30, 2019 | $93.70M | -66.8% |
| Q1 FY2019 | Mar 31, 2019 | $822.70M | +52.5% |
| Q4 FY2018 | Dec 31, 2018 | $643.30M | +40.1% |
| Q3 FY2018 | Sep 30, 2018 | $346.70M | -2.4% |
| Q2 FY2018 | Jun 30, 2018 | $282.60M | – |
| Q1 FY2018 | Mar 31, 2018 | $539.40M | +76.6% |
| Q4 FY2017 | Dec 31, 2017 | $459.30M | +91.4% |
| Q3 FY2017 | Sep 30, 2017 | $355.18M | – |
| Q2 FY2017 | Jun 30, 2017 | -$85.42M | – |
| Q1 FY2017 | Mar 31, 2017 | $305.44M | – |
| Q4 FY2016 | Dec 31, 2016 | $239.97M | – |
See a number that looks wrong?